Educational Background: BA in biology from St. Louis University; MD from University of Missouri-Columbia
Research Interests: My research interests are in the areas of lung cancer and testicular cancer. My lung cancer research has focused on the treatment of stage III and IV non-small cell lung cancer and extensive stage small cell lung cancer. I have led multiple phase II and III clinical trials in each of these disease states. I am also interested in studying novel therapies in the refractory setting of men with testicular cancer.
Dec. 29, 2016: Members of the Big Ten Cancer Research Consortium Steering Committee recently appointed Robert Kratzke, MD, as the committee's first chair, and Ruth O'Regan, MD, as its vice chair. Each will serve a one-year term, with Dr. O'Regan serving as chair in the subsequent year. Read More
Dec. 21, 2016: Fast away the old year passes, and the Big Ten Cancer Centers are bringing 2016 to a climactic close. Their amazing and world-changing work in the fight against cancer has not only made 2016 an unforgettable and truly historic year, but it also beckons the shining dawn of a promising new year full of hope for patients and researchers. Next year’s breakthroughs have been this year’s vision, and this year’s legacy becomes next year’s inspiration. Take a moment to reflect on recent breakthroughs which embody a year to remember, in 2016’s final Across the Consortium. Read More
Dec. 19, 2016: Andrea L. Kasinski, PhD Investigator Spotlight Andrea L. Kasinski, PhD Educational Background: PhD, Emory University (2009), Postdoctoral Fellow, Yale University Research Interests: My laboratory works on non-coding RNA biology and therapeutics. Specifically, we focus on identifying biologically important RNAs whose misexpression drives the tumorigenic process. We then utilize this information to design, develop, and implement RNA-based therapeutics. Specifically, evidence-based approaches are being developed to identify microRNAs that drive the process of tumorigenesis, or to identify microRNAs that are required for tumor cell maintenance or therapeutic resistance. Using this data, we then develop various strategies to alter the concentration of theses microRNAs in... Read More
Nov. 21, 2016: Patients with locally advanced bladder cancer often find themselves at a fork in the road when it comes to treatment decisions. The determining factor for many patients is whether or not they are candidates for surgery. For those who can have cisplatin based chemotherapy and can undergo surgery, the standard approach is often well defined; but for those who cannot, the road ahead is not so clear. A new Big Ten Cancer Research Consortium study, led by Monika Joshi, MD, MRCP, of Penn State Cancer Institute, may help to open new options for these patients. Read More
Nov. 18, 2016: In the season of gratitude, this month's edition of Across the Consortium recounts more reasons to be grateful for the collegial partnership of the Big Ten Cancer Centers in the fight against cancer. Get up to date on the stunning discoveries and monumental breakthroughs with far-reaching implications. Be inspired by accounts of leadership. Remember why we are stronger together. All this and more as we take you Across the Consortium! Read More
Nov. 2, 2016:Investigator SpotlightNatalie Callander, MD, is a hematologist at the University of Wisconsin Carbone Cancer Center who focuses on the treatment of patients with multiple myeloma, the second most common form of blood cancer. She serves as co-chair of the Big Ten CRC’s Multiple Myeloma Clinical Trial group, along with Dr. Craig Cole of the University of Michigan. “Our mission at the Big Ten CRC is to foster collaboration between researchers and industry partners in order to develop novel therapies, particularly for patients with relapsed... Read More
Oct. 19, 2016: October is National Breast Cancer Awareness month, and this month's Across the Consortium illustrates why the Big Ten CRC member institutions are leading the way. The team is heading off drug resistance at the pass, streamlining preventative measures, developing imaging technology, studying the role of diet, and pioneering treatment strategies where no targeted therapies presently exist. Catch up with the consortium that's transforming cancer research through collaboration. Read More
Oct. 5, 2016: Breast cancer is the second most common kind of cancer in women, behind skin cancer. About 1 in 8 women born today in the United States will get breast cancer at some point, according to the U.S. Department of Health and Human Services. Each year in the United States, more than 200,000 women get breast cancer and more than 40,000 women die from the disease. October is National Breast Cancer Awareness Month — a time to engage, mobilize, and learn — and the Big Ten Cancer Research Consortium brings a wealth of progress to the table. Read More
Oct. 5, 2016: The first-ever Big Ten Cancer Research Consortium Summit drew an energetic group of academic investigators and pharmaceutical industry leaders to Indianapolis Sept. 9-10, for a series of meetings that strengthened academic and pharmaceutical industry collaboration within the consortium. More than 100 attendees, representing all Big Ten CRC member institutions and 16 pharmaceutical and biotech companies, attended the event, hosted by the Indiana University Melvin and Bren Simon Cancer Center. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube